Vaccines for Immune Tolerance Against Autoimmune Disease

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2023 Nov 19

PMID 37980949

Authors

April Kim

Fang Xie

Omar A Abed

James J Moon

Affiliations

Soon will be listed here.

Abstract

The high prevalence and rising incidence of autoimmune diseases have become a prominent public health issue. Autoimmune disorders result from the immune system erroneously attacking the body's own healthy cells and tissues, causing persistent inflammation, tissue injury, and impaired organ function. Existing treatments primarily rely on broad immunosuppression, leaving patients vulnerable to infections and necessitating lifelong treatments. To address these unmet needs, an emerging frontier of vaccine development aims to restore immune equilibrium by inducing immune tolerance to autoantigens, offering a potential avenue for a cure rather than mere symptom management. We discuss this burgeoning field of vaccine development against inflammation and autoimmune diseases, with a focus on common autoimmune disorders, including multiple sclerosis, type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. Vaccine-based strategies provide a new pathway for the future of autoimmune disease therapeutics, heralding a new era in the battle against inflammation and autoimmunity.

Citing Articles

Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines.

Vo D, Trinh K Vaccines (Basel). 2025; 13(2).

PMID: 40006737 PMC: 11860421. DOI: 10.3390/vaccines13020191.

A comprehensive review of paratuberculosis in animals and its implications for public health.

Meles D, Mustofa I, Khairullah A, Wurlina W, Mustofa R, Suwasanti N Open Vet J. 2024; 14(11):2731-2744.

PMID: 39737030 PMC: 11682747. DOI: 10.5455/OVJ.2024.v14.i11.2.

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.

Shi Y, Shi M, Wang Y, You J Signal Transduct Target Ther. 2024; 9(1):322.

PMID: 39543114 PMC: 11564800. DOI: 10.1038/s41392-024-02002-z.

Advances in Type 1 Diabetes Mellitus Management in Children.

Bahal M, Pande V, Dua J, Mane S Cureus. 2024; 16(8):e67377.

PMID: 39310514 PMC: 11416143. DOI: 10.7759/cureus.67377.

Revolutionizing rheumatoid arthritis therapy: harnessing cytomembrane biomimetic nanoparticles for novel treatment strategies.

Ma L, Jiang X, Gao J Drug Deliv Transl Res. 2024; 15(1):66-83.

PMID: 38758497 DOI: 10.1007/s13346-024-01605-x.

References

Anderson R, Jabri B . Vaccine against autoimmune disease: antigen-specific immunotherapy. Curr Opin Immunol. 2013; 25(3):410-7. PMC: 3753082. DOI: 10.1016/j.coi.2013.02.004. View

Powell J, Lerner C, Schwartz R . Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol. 1999; 162(5):2775-84. View

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

Zimmer R, Scherbarth H, Rillo O, Gomez-Reino J, Muller S . Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2012; 72(11):1830-5. PMC: 3812851. DOI: 10.1136/annrheumdis-2012-202460. View

Kang H, Michaels M, Berner B, Datta S . Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol. 2005; 174(6):3247-55. DOI: 10.4049/jimmunol.174.6.3247. View

Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A . A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes. 2008; 57(6):1544-55. PMC: 2713034. DOI: 10.2337/db07-0507. View

Ghasemi N, Razavi S, Nikzad E . Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017; 19(1):1-10. PMC: 5241505. DOI: 10.22074/cellj.2016.4867. View

Cho J, Stewart J, Drashansky T, Brusko M, Zuniga A, Lorentsen K . An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis. Biomaterials. 2017; 143:79-92. PMC: 5870833. DOI: 10.1016/j.biomaterials.2017.07.029. View

Thi T, Priemel P, Karrout Y, Driss V, Delbeke M, Dendooven A . Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis. Int J Pharm. 2017; 533(1):26-33. DOI: 10.1016/j.ijpharm.2017.09.037. View

10.

Smallwood T, Giacomin P, Loukas A, Mulvenna J, Clark R, Miles J . Helminth Immunomodulation in Autoimmune Disease. Front Immunol. 2017; 8:453. PMC: 5401880. DOI: 10.3389/fimmu.2017.00453. View

11.

Schmidt A, Oberle N, Krammer P . Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012; 3:51. PMC: 3341960. DOI: 10.3389/fimmu.2012.00051. View

12.

Hovav A . Dendritic cells of the oral mucosa. Mucosal Immunol. 2013; 7(1):27-37. DOI: 10.1038/mi.2013.42. View

13.

Glatigny S, Bettelli E . Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS). Cold Spring Harb Perspect Med. 2018; 8(11). PMC: 6211376. DOI: 10.1101/cshperspect.a028977. View

14.

Beatty P, Ranganathan S, Finn O . Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology. 2012; 1(3):263-270. PMC: 3382848. DOI: 10.4161/onci.18950. View

15.

Sonigra A, Nel H, Wehr P, Ramnoruth N, Patel S, van Schie K . Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis. JCI Insight. 2022; 7(20). PMC: 9714780. DOI: 10.1172/jci.insight.160964. View

16.

Kaliyaperumal A, Michaels M, Datta S . Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol. 2002; 168(5):2530-7. DOI: 10.4049/jimmunol.168.5.2530. View

17.

Cremel M, Guerin N, Horand F, Banz A, Godfrin Y . Red blood cells as innovative antigen carrier to induce specific immune tolerance. Int J Pharm. 2013; 443(1-2):39-49. DOI: 10.1016/j.ijpharm.2012.12.044. View

18.

Katarzyna P, Wiktor S, Ewa D, Piotr L . Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatol Int. 2023; 43(8):1395-1407. PMC: 10261264. DOI: 10.1007/s00296-023-05306-5. View

19.

Skyler J, Krischer J, Wolfsdorf J, Cowie C, Palmer J, Greenbaum C . Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28(5):1068-76. DOI: 10.2337/diacare.28.5.1068. View

20.

Schall N, Muller S . Resetting the autoreactive immune system with a therapeutic peptide in lupus. Lupus. 2015; 24(4-5):412-8. DOI: 10.1177/0961203314556138. View